Immunotherapy for multiple myeloma: new chances and hope

Jingyu Xu; Gang An; Lugui Qiu

doi:10.20892/j.issn.2095-3941.2023.0258

References

1.↵
2. van de Donk NWCJ,
3. Pawlyn C,
4. Yong KL.
Multiple myeloma. Lancet. 2021; 397: 410–27.
OpenUrl CrossRef
2.↵
2. Joseph NS,
3. Kaufman JL,
4. Dhodapkar MV,
5. Hofmeister CC,
6. Almaula DK,
7. Heffner LT, et al.
Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020; 38: 1928–37.
OpenUrl CrossRef PubMed
3.↵
2. Dima D,
3. Jiang D,
4. Singh DJ,
5. Hasipek M,
6. Shah HS,
7. Ullah F, et al.
Multiple myeloma therapy: emerging trends and challenges. Cancers (Basel). 2022; 14: 4082.
OpenUrl
4.↵
2. Voorhees PM,
3. Kaufman JL,
4. Laubach J,
5. Sborov DW,
6. Reeves B,
7. Rodriguez C, et al.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the griffin trial. Blood. 2020; 136: 936–45.
OpenUrl PubMed
5.↵
2. Attal M,
3. Richardson PG,
4. Rajkumar SV,
5. San-Miguel J,
6. Beksac M,
7. Spicka I, et al.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet (London, England). 2019; 394: 2096–107.
OpenUrl
6.↵
2. Dimopoulos MA,
3. Richardson PG,
4. Bahlis NJ,
5. Grosicki S,
6. Cavo M,
7. Beksaç M, et al.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet. Haematol. 2022; 9: e403–14.
OpenUrl
7.↵
2. Dimopoulos MA,
3. Dytfeld D,
4. Grosicki S,
5. Moreau P,
6. Takezako N,
7. Hori M, et al.
Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol. 2023; 41: 568–78.
OpenUrl
8.↵
2. Tai YT,
3. Acharya C,
4. An G,
5. Moschetta M,
6. Zhong MY,
7. Feng X, et al.
April and bcma promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016; 127: 3225–36.
OpenUrl Abstract/FREE Full Text
9.↵
2. Munshi NC,
3. Anderson LD Jr.,
4. Shah N,
5. Madduri D,
6. Berdeja J,
7. Lonial S, et al.
Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384: 705–16.
OpenUrl CrossRef PubMed
10.↵
2. Martin T,
3. Usmani SZ,
4. Berdeja JG,
5. Agha M,
6. Cohen AD,
7. Hari P, et al.
Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023; 41: 1265–74.
OpenUrl CrossRef
11.↵
2. Parikh RH,
3. Lonial S.
Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023; 73: 275–85.
OpenUrl
12.↵
2. Xia J,
3. Li H,
4. Yan Z,
5. Zhou D,
6. Wang Y,
7. Qi Y, et al.
Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023; 41: 2583–93.
OpenUrl
13.↵
2. Moreau P,
3. Garfall AL,
4. van de Donk N,
5. Nahi H,
6. San-Miguel JF,
7. Oriol A, et al.
Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022; 387: 495–505.
OpenUrl CrossRef
14.↵
2. Sebag M,
3. Raje NS,
4. Bahlis NJ,
5. Costello C,
6. Dholaria B,
7. Solh M, et al.
Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1. Blood. 2021; 138: 895.
OpenUrl
15.↵
2. Chari A,
3. Minnema MC,
4. Berdeja JG,
5. Oriol A,
6. van de Donk N,
7. Rodríguez-Otero P, et al.
Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022; 387: 2232–44.
OpenUrl
16.↵
2. Lonial S,
3. Lee HC,
4. Badros A,
5. Trudel S,
6. Nooka AK,
7. Chari A, et al.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020; 21: 207–21.
OpenUrl CrossRef PubMed
17.↵
2. Cohen AD,
3. Mateos MV,
4. Cohen YC,
5. Rodriguez-Otero P,
6. Paiva B,
7. van de Donk N, et al.
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other bcma-targeting agents. Blood. 2023; 141: 219–30.
OpenUrl
18.↵
2. Ferreri CJ,
3. Hildebrandt MAT,
4. Hashmi H,
5. Shune LO,
6. McGuirk JP,
7. Sborov DW, et al.
Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma (RRMM) who have received a prior bcma-targeted therapy: real world, multi-institutional experience. Blood. 2022; 140: 1856–58.
OpenUrl
19.↵
2. Van de Donk NW,
3. Agha M,
4. Cohen AD,
5. Cohen YC,
6. Anguille S,
7. Kerre T, et al.
Ciltacabtagene autoleucel (Cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2 cohort B 18-month follow-up. Blood. 2022; 140: 7536–37.
OpenUrl
20.↵
2. Shi X,
3. Yan L,
4. Shang J,
5. Kang L,
6. Yan Z,
7. Jin S, et al.
Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol. 2022; 97: 537–47.
OpenUrl

In this issue

Download PDF

Email Article

Citation Tools

Cited By...

No citing articles found.

Google Scholar

More in this TOC Section

Show more Editorial

[1] 1.↵

van de Donk NWCJ,
Pawlyn C,
Yong KL.
Multiple myeloma. Lancet. 2021; 397: 410–27.
OpenUrl CrossRef

[3] van de Donk NWCJ,

[4] Pawlyn C,

[5] Yong KL.

[6] 2.↵

Joseph NS,
Kaufman JL,
Dhodapkar MV,
Hofmeister CC,
Almaula DK,
Heffner LT, et al.
Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020; 38: 1928–37.
OpenUrl CrossRef PubMed

[8] Joseph NS,

[9] Kaufman JL,

[10] Dhodapkar MV,

[11] Hofmeister CC,

[12] Almaula DK,

[13] Heffner LT, et al.

[14] 3.↵

Dima D,
Jiang D,
Singh DJ,
Hasipek M,
Shah HS,
Ullah F, et al.
Multiple myeloma therapy: emerging trends and challenges. Cancers (Basel). 2022; 14: 4082.
OpenUrl

[16] Dima D,

[17] Jiang D,

[18] Singh DJ,

[19] Hasipek M,

[20] Shah HS,

[21] Ullah F, et al.

[22] 4.↵

Voorhees PM,
Kaufman JL,
Laubach J,
Sborov DW,
Reeves B,
Rodriguez C, et al.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the griffin trial. Blood. 2020; 136: 936–45.
OpenUrl PubMed

[24] Voorhees PM,

[25] Kaufman JL,

[26] Laubach J,

[27] Sborov DW,

[28] Reeves B,

[29] Rodriguez C, et al.

[30] 5.↵

Attal M,
Richardson PG,
Rajkumar SV,
San-Miguel J,
Beksac M,
Spicka I, et al.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet (London, England). 2019; 394: 2096–107.
OpenUrl

[32] Attal M,

[33] Richardson PG,

[34] Rajkumar SV,

[35] San-Miguel J,

[36] Beksac M,

[37] Spicka I, et al.

[38] 6.↵

Dimopoulos MA,
Richardson PG,
Bahlis NJ,
Grosicki S,
Cavo M,
Beksaç M, et al.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet. Haematol. 2022; 9: e403–14.
OpenUrl

[40] Dimopoulos MA,

[41] Richardson PG,

[42] Bahlis NJ,

[43] Grosicki S,

[44] Cavo M,

[45] Beksaç M, et al.

[46] 7.↵

Dimopoulos MA,
Dytfeld D,
Grosicki S,
Moreau P,
Takezako N,
Hori M, et al.
Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol. 2023; 41: 568–78.
OpenUrl

[48] Dimopoulos MA,

[49] Dytfeld D,

[50] Grosicki S,

[51] Moreau P,

[52] Takezako N,

[53] Hori M, et al.

[54] 8.↵

Tai YT,
Acharya C,
An G,
Moschetta M,
Zhong MY,
Feng X, et al.
April and bcma promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016; 127: 3225–36.
OpenUrl Abstract/FREE Full Text

[56] Tai YT,

[57] Acharya C,

[58] An G,

[59] Moschetta M,

[60] Zhong MY,

[61] Feng X, et al.

[62] 9.↵

Munshi NC,
Anderson LD Jr.,
Shah N,
Madduri D,
Berdeja J,
Lonial S, et al.
Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384: 705–16.
OpenUrl CrossRef PubMed

[64] Munshi NC,

[65] Anderson LD Jr.,

[66] Shah N,

[67] Madduri D,

[68] Berdeja J,

[69] Lonial S, et al.

[70] 10.↵

Martin T,
Usmani SZ,
Berdeja JG,
Agha M,
Cohen AD,
Hari P, et al.
Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023; 41: 1265–74.
OpenUrl CrossRef

[72] Martin T,

[73] Usmani SZ,

[74] Berdeja JG,

[75] Agha M,

[76] Cohen AD,

[77] Hari P, et al.

[78] 11.↵

Parikh RH,
Lonial S.
Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023; 73: 275–85.
OpenUrl

[80] Parikh RH,

[81] Lonial S.

[82] 12.↵

Xia J,
Li H,
Yan Z,
Zhou D,
Wang Y,
Qi Y, et al.
Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023; 41: 2583–93.
OpenUrl

[84] Xia J,

[85] Li H,

[86] Yan Z,

[87] Zhou D,

[88] Wang Y,

[89] Qi Y, et al.

[90] 13.↵

Moreau P,
Garfall AL,
van de Donk N,
Nahi H,
San-Miguel JF,
Oriol A, et al.
Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022; 387: 495–505.
OpenUrl CrossRef

[92] Moreau P,

[93] Garfall AL,

[94] van de Donk N,

[95] Nahi H,

[96] San-Miguel JF,

[97] Oriol A, et al.

[98] 14.↵

Sebag M,
Raje NS,
Bahlis NJ,
Costello C,
Dholaria B,
Solh M, et al.
Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1. Blood. 2021; 138: 895.
OpenUrl

[100] Sebag M,

[101] Raje NS,

[102] Bahlis NJ,

[103] Costello C,

[104] Dholaria B,

[105] Solh M, et al.

[106] 15.↵

Chari A,
Minnema MC,
Berdeja JG,
Oriol A,
van de Donk N,
Rodríguez-Otero P, et al.
Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022; 387: 2232–44.
OpenUrl

[108] Chari A,

[109] Minnema MC,

[110] Berdeja JG,

[111] Oriol A,

[112] van de Donk N,

[113] Rodríguez-Otero P, et al.

[114] 16.↵

Lonial S,
Lee HC,
Badros A,
Trudel S,
Nooka AK,
Chari A, et al.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020; 21: 207–21.
OpenUrl CrossRef PubMed

[116] Lonial S,

[117] Lee HC,

[118] Badros A,

[119] Trudel S,

[120] Nooka AK,

[121] Chari A, et al.

[122] 17.↵

Cohen AD,
Mateos MV,
Cohen YC,
Rodriguez-Otero P,
Paiva B,
van de Donk N, et al.
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other bcma-targeting agents. Blood. 2023; 141: 219–30.
OpenUrl

[124] Cohen AD,

[125] Mateos MV,

[126] Cohen YC,

[127] Rodriguez-Otero P,

[128] Paiva B,

[129] van de Donk N, et al.

[130] 18.↵

Ferreri CJ,
Hildebrandt MAT,
Hashmi H,
Shune LO,
McGuirk JP,
Sborov DW, et al.
Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma (RRMM) who have received a prior bcma-targeted therapy: real world, multi-institutional experience. Blood. 2022; 140: 1856–58.
OpenUrl

[132] Ferreri CJ,

[133] Hildebrandt MAT,

[134] Hashmi H,

[135] Shune LO,

[136] McGuirk JP,

[137] Sborov DW, et al.

[138] 19.↵

Van de Donk NW,
Agha M,
Cohen AD,
Cohen YC,
Anguille S,
Kerre T, et al.
Ciltacabtagene autoleucel (Cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2 cohort B 18-month follow-up. Blood. 2022; 140: 7536–37.
OpenUrl

[140] Van de Donk NW,

[141] Agha M,

[142] Cohen AD,

[143] Cohen YC,

[144] Anguille S,

[145] Kerre T, et al.

[146] 20.↵

Shi X,
Yan L,
Shang J,
Kang L,
Yan Z,
Jin S, et al.
Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol. 2022; 97: 537–47.
OpenUrl

[148] Shi X,

[149] Yan L,

[150] Shang J,

[151] Kang L,

[152] Yan Z,

[153] Jin S, et al.

Main menu

User menu

Search

Immunotherapy for multiple myeloma: new chances and hope

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Navigate

More Information

For Authors

Journal Services

Main menu

User menu

Search

Immunotherapy for multiple myeloma: new chances and hope

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Navigate

More Information

For Authors

Journal Services